Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management.
- 1SHATC Medica Cor, Riga 35, 7013 Ruse, Bulgaria.
- 2Medical University of Pleven, 5800 Pleven, Bulgaria.
- 3Faculty of Public Health and Health Care, Ruse University "Angel Kanchev", 7017 Ruse, Bulgaria.
Abstract
Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous myocardial disease characterized by unexplained left ventricular hypertrophy and a broad spectrum of clinical manifestations, ranging from an asymptomatic phenotype to heart failure, atrial and ventricular arrhythmias, sudden cardiac death, and advanced heart failure. Accurate diagnosis and risk stratification therefore require complex assessment. Multimodality cardiovascular imaging provides complementary structural, functional, and tissue characterization that cannot be obtained using a single imaging technique. Transthoracic echocardiography remains the cornerstone of initial diagnosis, hemodynamic assessment, and longitudinal follow-up, while advanced echocardiographic techniques provide additional information regarding myocardial and left atrial mechanics. Cardiac magnetic resonance (CMR) has become central to phenotypic characterization and tissue assessment. Cardiac computed tomography offers complementary high-resolution anatomical information, particularly for coronary assessment and procedural planning, whereas nuclear imaging, provides insights into coronary microvascular dysfunction, myocardial perfusion, and selected phenocopies such as transthyretin cardiac amyloidosis. Multimodality imaging also facilitates differentiation of HCM from other conditions such as athlete's heart, hypertensive heart disease, and infiltrative cardiomyopathies. Integration of imaging biomarkers with clinical and genetic information may improve prediction of adverse outcomes. Thus, multimodality imaging should be regarded not as a collection of competing techniques but as an integrated framework for precision diagnosis, risk stratification, therapeutic planning, and longitudinal management of patients with HCM.
Related
- Left Ventricular Wall Thickness in Hypertrophic Cardiomyopathy and Cardiac Amyloidosis: A Multimodality Imaging Comparison
- HCM-PhenotypeNet: Deep Multimodal Phenotyping of Hypertrophic Cardiomyopathy from Echocardiographic Video and Clinical Data
- Transatrial air-assisted epicardial ventricular tachycardia ablation for hypertrophic cardiomyopathy and management of postprocedural right atrial thrombus.
- The Evolving Landscape of Hypertrophic Cardiomyopathy: Clinical Assessment, Precision Therapies, and Emerging Strategies
- Life-long management of atrial fibrillation in a patient with hypertrophic obstructive cardiomyopathy following alcohol septal ablation: A10-year follow-up case report
BibTeX
@article{mileva2026multimodality,
title = {{Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management.}},
author = {Niya Mileva and Panayot Panayotov},
journal = {Diagnostics (Basel, Switzerland)},
year = {2026},
month = sep,
doi = {10.3390/diagnostics16193149},
url = {https://europepmc.org/article/MED/42882305},
note = {CC BY},
}
RIS
TY - JOUR
TI - Multimodality Imaging in Hypertrophic Cardiomyopathy: From Phenotyping to Precision Clinical Management.
AU - Niya Mileva
AU - Panayot Panayotov
PY - 2026
DA - 2026/09/28
JO - Diagnostics (Basel, Switzerland)
DO - 10.3390/diagnostics16193149
UR - https://europepmc.org/article/MED/42882305
AB - Hypertrophic cardiomyopathy (HCM) is a genetically and phenotypically heterogeneous myocardial disease characterized by unexplained left ventricular hypertrophy and a broad spectrum of clinical manifestations, ranging from an asymptomatic phenotype to heart failure, atrial and ventricular arrhythmias, sudden cardiac death, and advanced heart failure. Accurate diagnosis and risk stratification therefore require complex assessment. Multimodality cardiovascular imaging provides complementary structural, functional, and tissue characterization that cannot be obtained using a single imaging technique. Transthoracic echocardiography remains the cornerstone of initial diagnosis, hemodynamic assessment, and longitudinal follow-up, while advanced echocardiographic techniques provide additional information regarding myocardial and left atrial mechanics. Cardiac magnetic resonance (CMR) has become central to phenotypic characterization and tissue assessment. Cardiac computed tomography offers complementary high-resolution anatomical information, particularly for coronary assessment and procedural planning, whereas nuclear imaging, provides insights into coronary microvascular dysfunction, myocardial perfusion, and selected phenocopies such as transthyretin cardiac amyloidosis. Multimodality imaging also facilitates differentiation of HCM from other conditions such as athlete's heart, hypertensive heart disease, and infiltrative cardiomyopathies. Integration of imaging biomarkers with clinical and genetic information may improve prediction of adverse outcomes. Thus, multimodality imaging should be regarded not as a collection of competing techniques but as an integrated framework for precision diagnosis, risk stratification, therapeutic planning, and longitudinal management of patients with HCM.
SN - 2075-4418
ER -